S100A9 and atrial fibrillation: Moreover, pharmacologic reactivation of NF-κB using HY-18739 reversed the protective effects conferred by S100A9 deletion, restoring AF inducibility, impairing cardiac function, and increasing fibrosis markers such as collagen-1 and α-SMA.